PCSK9 inhibitors, a new type of therapy, has arrived and appear to be an effective therapy for lowering LDL cholesterol to a level that exceeds the current standard of care.
Recently, the results from a clinical trial at Brigham and Women’s Hospital showed that the drug evolocumab, when combined with statins, significantly and safely reduced the risk of cardiovascular events.
Read more
Comments are closed.